Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Fred Ederer is active.

Publication


Featured researches published by Fred Ederer.


The New England Journal of Medicine | 1993

Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood

Jack S. Mandel; John H. Bond; Timothy R. Church; Dale C. Snover; G. Mary Bradley; Leonard M. Schuman; Fred Ederer

BACKGROUND Although tests for occult blood in the feces are widely used to screen for colorectal cancers, there is no conclusive evidence that they reduce mortality from this cause. We evaluated a fecal occult-blood test in a randomized trial and documented its effectiveness. METHODS We randomly assigned 46,551 participants 50 to 80 years of age to screening for colorectal cancer once a year, to screening every two years, or to a control group. Participants who were screened submitted six guaiac-impregnated paper slides with two smears from each of three consecutive stools. About 83 percent of the slides were rehydrated. Participants who tested positive underwent a diagnostic evaluation that included colonoscopy. Vital status was ascertained for all study participants during 13 years of follow-up. A committee determined causes of death. A single pathologist determined the stage of each tissue specimen. Differences in mortality from colorectal cancer, the primary study end point, were monitored with the sequential log-rank statistic. RESULTS The 13-year cumulative mortality per 1000 from colorectal cancer was 5.88 in the annually screened group (95 percent confidence interval, 4.61 to 7.15), 8.33 in the biennially screened group (95 percent confidence interval, 6.82 to 9.84), and 8.83 in the control group (95 percent confidence interval, 7.26 to 10.40). The rate in the annually screened group, but not in the biennially screened group, was significantly lower than that in the control group. Reduced mortality in the annually screened group was accompanied by improved survival in those with colorectal cancer and a shift to detection at an earlier stage of cancer. CONCLUSIONS Annual fecal occult-blood testing with rehydration of the samples decreased the 13-year cumulative mortality from colorectal cancer by 33 percent.


The New England Journal of Medicine | 2000

THE EFFECT OF FECAL OCCULT-BLOOD SCREENING ON THE INCIDENCE OF COLORECTAL CANCER

Jack S. Mandel; Timothy R. Church; John H. Bond; Fred Ederer; Mindy S. Geisser; Steven J. Mongin; Dale C. Snover; Leonard M. Schuman

BACKGROUND Both annual testing for fecal occult blood and biennial testing significantly reduce mortality from colorectal cancer. However, the effect of screening on the incidence of colorectal cancer remains uncertain, despite the diagnosis and removal of precancerous lesions in many persons who undergo screening. METHODS We followed the participants in the Minnesota Colon Cancer Control Study for 18 years. A total of 46,551 people, most of whom were 50 to 80 years old, were enrolled between 1975 and 1978 and randomly assigned to annual screening, biennial screening, or usual care (the control group). Those assigned to the screening groups were asked to prepare and submit two samples from each of three consecutive stools for guaiac-based testing. Those with at least one positive slide in the set of six were offered a diagnostic examination that included colonoscopy. Screening was conducted between 1976 and 1982 and again between 1986 and 1992. Study participants have been followed with respect to newly diagnosed cases of colorectal cancer and deaths. Follow-up has been more than 90 percent complete. RESULTS During the 18-year follow-up period, we identified 1359 new cases of colorectal cancer: 417 in the annual-screening group, 435 in the biennial-screening group, and 507 in the control group. The cumulative incidence ratios for colorectal cancer in the screening groups as compared with the control group were 0.80 (95 percent confidence interval, 0.70 to 0.90) and 0.83 (95 percent confidence interval, 0.73 to 0.94) for the annual-screening and biennial-screening groups, respectively. For both screening groups, the number of positive slides was associated with the positive predictive value both for colorectal cancer and for adenomatous polyps at least 1 cm in diameter. CONCLUSIONS The use of either annual or biennial fecal occult-blood testing significantly reduces the incidence of colorectal cancer.


Gastroenterology | 1989

Sensitivity, specificity, and positive predictivity of the Hemoccult test in screening for colorectal cancers. The University of Minnesota's Colon Cancer Control Study.

Jack S. Mandel; John H. Bond; Mary Bradley; Dale C. Snover; Timothy R. Church; Stanley E. Williams; Gavin D. Watt; Leonard M. Schuman; Fred Ederer; Victor A. Gilbertsen

Data are presented on the sensitivity, specificity, and positive predictivity of the Hemoccult test based on the experience of the Minnesota Colon Cancer Control Study, a randomized clinical trial to determine whether the use of the Hemoccult test can reduce mortality from colorectal cancer. Rehydrating the slides with a drop of water before processing resulted in an increase in positivity (2.4% to 9.8%), and sensitivity (80.8% to 92.2%) but a decrease in specificity (97.7% to 90.4%) and positive predictivity (5.6% to 2.2%). The effects of age and sex were also evaluated. The test was less specific for men than women (p = 0.03). Specificity was highest for those less than 60 yr of age and decreased with increasing age (p = 0.05). The positive predictivity increased with age from 1.6% for those under 60 yr to 3.6% for those over 70 yr (p = 0.0004).


Journal of Clinical Epidemiology | 1999

Colorectal cancer deaths as determined by expert committee and from death certificate : A comparison. The Minnesota Study

Fred Ederer; Mindy S. Geisser; Steven J. Mongin; Timothy R. Church; Jack S. Mandel

For deaths during the first 13 years of follow-up of the Minnesota Colon Cancer Control Study, an expert committee using numerous medical documents, and a nosologist using only the death certificate independently determined whether colorectal cancer caused the death and, if not, whether the disease was present at death. Deaths due to colorectal cancer numbered 318 according to the nosologist and 323 according to the committee, a discrepancy of 1.5%, which is similar in magnitude to that in three previous studies. The nosologist and committee agreed that colorectal cancer caused the death in each of 290 individual cases; they disagreed widely on the number of deaths from other causes but with colorectal cancer. If it is important to know only the gross number of deaths from colorectal cancer, then the death certificate alone appears to be sufficiently accurate; if it is important to know the cause of death of individual subjects or the number dying from other causes but with colorectal cancer, then the expert committee method provides more accurate information.


Journal of the National Cancer Institute | 1999

Colorectal Cancer Mortality: Effectiveness of Biennial Screening for Fecal Occult Blood

Jack S. Mandel; Timothy R. Church; Fred Ederer; John H. Bond


Journal of the National Cancer Institute | 1997

Fecal occult blood screening in the Minnesota study : Sensitivity of the screening test

Timothy R. Church; Fred Ederer; Jack S. Mandel


Journal of the National Cancer Institute | 1997

Fecal Occult Blood Screening in the Minnesota Study: Role of Chance Detection of Lesions

Fred Ederer; Timothy R. Church; Jack S. Mandel


Gastroenterology | 1989

Sensitivity, Specificity, and Positive Predictivity of the Hemoccult Test in Screening for Colorectal Cancers

Jack S. Mandel; John H. Bond; Mary Bradley; Dale C. Snover; Timothy R. Church; Stanley E. Williams; Gavin D. Watt; Leonard M. Schuman; Fred Ederer; Victor A. Gilbertsen


American Journal of Epidemiology | 1993

Estimating the Duration of Ongoing Prevention Trials

Timothy R. Church; Fred Ederer; Jack S. Mandel; Gavin D. Watt; Mindy S. Geisser


JAMA | 1994

Screening for Colorectal Cancer: Which Test Is Best?

Jack S. Mandel; Fred Ederer; Timothy R. Church; John H. Bond

Collaboration


Dive into the Fred Ederer's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

John H. Bond

University of Minnesota

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mary Bradley

University of Minnesota

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge